icon-folder.gif   Conference Reports for NATAP  
 
  AASLD
The Liver Meeting
Boston MA
November 2016
Back grey_arrow_rt.gif
 
 
 
Six weeks of sofosbuvir/ledipasvir treatment of acute hepatitis C virus genotype 1 mono-infection: Final results of The German HepNet Acute HCV IV Study......55% were sexual transmission including 5 MSM
 
 
  Reported by Jules Levin
AASLD 2016 Nov 11-16 Boston, MA
 
Katja Deterding1,11, Christoph Spinner2, Eckart Schott3, Tania Welzel4, Guido Gerken5, Hartwig Klinker6, Ulrich Spengler7, Johannes Wiegand8, Julian Schulze zur Wiesch9, Anita Pathil10, Markus Cornberg1,11,12, Andreas Umgelter2, Caroline Zöllner3, Stefan Zeuzem4, Armin Papkalla13, Kristina Weber14, Svenja Hardtke11,12, Heiko von der Leyen13, Armin Koch14, Dorothee von Witzendorff11, Michael P. Manns1,11,12, Heiner Wedemeyer1,11,12, the HepNet Acute HCV IV Study Group
 
1. Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany, 2. Department of Medicine II, University Hospital Klinikum rechts der Isar, Munich, Germany, 3. Department of Hepatology and Gastroenterology, Charite Universitätsmedizin Berlin, Berlin, Germany, 4. Department of Medicine, University Hospital Frankfurt, Frankfurt, Germany, 5. Department of Gastroenterology and Hepatology, University Hospital Essen, Essen, Germany, 6. Department of Internal Medicine II, Div. of Infectious Diseases, University of Wurzburg Medical Center, Wurzburg, Germany, 7. Department of Internal Medicine I, University Hospital Bonn, Bonn, Germany, 8. Department of Gastroenterology and Rheumatology, Section of Hepatology, University of Leipzig, Leipzig, Germany, 9. Department of Internal Medicine, University Hospital Hamburg-Eppendorf, Hamburg, Germany, 10. Department of Internal Medicine IV, Gastroenterology and Hepatology, University Clinic of Heidelberg, Heidelberg, Germany, 11. HepNet Study-House, project of the German Liver Foundation, 12. German Centre for Infection Research (DZIF), partner side Hannover-Braunschweig, 13. Hannover Clinical Trial Center GmbH, Hannover, Germany, 14. Department of Biostatistics, Hannover Medical School, Hannover, Germany
 
This study was supported by the HepNet Study House/German Liver Foundation and the German Centre for Infection Research (DZIF)

HCV1

HCV2

HCV3